AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05481970
Drug: dexmedetomidine,ketamine,lidocaine,propofol
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
Trial: NCT04890470
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal administration of oxytocin (24 IU)
Trial: NCT04890470
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal administration of vasopressin (20 IU)
Trial: NCT05599971
Drug: intralesional combined digoxin and furosemide
RxNorm normalized name: furosemide and potassium
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
Trial: NCT06250504
Drug: Tenofovir Disoproxil, Lamuvidine and Dolutegravir
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
Trial: NCT04848272
Drug: Lanadelumab
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monoclonal antibody that targets active plasma kallikrein
Trial: NCT06228443
Drug: Leflunomide 20 mg Film-coated Tablet
RxNorm normalized name: leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide 20 mg Film-coated Tablet (Test Drug)
Trial: NCT06631989
Drug: WSD0922-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO
Trial: NCT04157075
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivicaine injection into uterosacral ligaments prior to colpotomy
Trial: NCT06234072
Drug: Astragalus + Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
Trial: NCT06234072
Drug: Gemcitabine alone
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
Trial: NCT04907812
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
Trial: NCT05206812
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)
Trial: NCT06229210
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 42 mg capsules administered orally, once daily
Trial: NCT00002413
Drug: Emivirine
RxNorm normalized name: Emivirine
DrugBank: Emivirine (DB08188)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05878535
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
Trial: NCT05298228
Drug: Remimazolam bolus does administration
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
Trial: NCT04602117
Drug: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly.
Trial: NCT06153368
Drug: Cadonilimab+mFOLFIRINOX
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle.
Trial: NCT06321913
Drug: IBI343 combined with IBI308
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
Trial: NCT06011785
Drug: Silica 12CH
RxNorm normalized name: Silica
DrugBank: Silicon dioxide (DB11132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
Trial: NCT05478772
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 12 mg on Day 1 and Day 7
Trial: NCT05478772
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg once daily on Days 3 through to Day 8
Trial: NCT06110195
Drug: Xevinapant
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
Trial: NCT06110195
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given with radiation weekly for 7 doses.
Trial: NCT06110195
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given with radiation weekly for 7 doses.
Trial: NCT02541643
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~* H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~* H2 blocker: ranitidine (50mg IV) or equivalent~* acetaminophen (650-1000mg PO)
Trial: NCT06725498
Drug: Tislelizumab-jsgr
RxNorm normalized name: tislelizumab-jsgr
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, Q3W
Trial: NCT06725498
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-75 mg/㎡, Q3W
Trial: NCT06725498
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 260 mg/㎡, Q3W
Trial: NCT04642378
Drug: iNCDSS based insulin regime
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
Trial: NCT04642378
Drug: routine insulin treatment regime
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients of this group will receive the insulin regime recommended by professional endocrinologists.
Trial: NCT05688696
Drug: Orelabrutinib (Low Dose)
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
Trial: NCT05688696
Drug: Orelabrutinib (High Dose)
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
Trial: NCT05688696
Drug: Orelabrutinib Placebo
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
Trial: NCT04605185
Drug: Donafenib Tosilate Tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg Qd/150mg Qd/100mg Bid, po
Trial: NCT05376930
Drug: DWP16001 Amg
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 Amg, Tablets, Orally, Once daily
Trial: NCT06553287
Drug: Vehicle BID
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vehicle matched to LNK01004 ointment for topical application.
Trial: NCT05311930
Drug: 2.5mg/d Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
Trial: NCT04517110
Drug: Pregabalin 300 mg
RxNorm normalized name: pregabalin 300 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 300 mg, capsule
Trial: NCT04517110
Drug: Pregabalin 75 mg
RxNorm normalized name: pregabalin 75 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 75 mg twice daily, capsules
Trial: NCT06344429
Drug: Single vision Lenses+0.05% atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~C Group：0.05% Atropine with single vision
Trial: NCT04517110
Drug: Pregabalin 300 mg Placebo
RxNorm normalized name: pregabalin 300 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo, matching Pregabalin 300 mg capsule
Trial: NCT04517110
Drug: Pregabalin 75 mg Placebo
RxNorm normalized name: pregabalin 75 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo, matching Pregabalin 75 mg capsules
Trial: NCT05139095
Drug: Camrelizumab plus apatinib CohortA
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
Trial: NCT05139095
Drug: Camrelizumab plus apatinib Cohort B
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
Trial: NCT06087731
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (8mg/kg) every 4 wekks
Trial: NCT06183918
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
Trial: NCT06555471
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab: 200mg iv q3w d1
Trial: NCT06555471
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
Trial: NCT06174116
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
Trial: NCT05453955
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
Trial: NCT05453955
Drug: Remimazolam Besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Trial: NCT00004194
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04731922
Drug: TAK-510
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-510 solution.
Trial: NCT04629976
Drug: NCO-48 Fumarate 4 mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 2mg NCO-48 Fumarate over 28 days of therapy
Trial: NCT04629976
Drug: NCO-48 Fumarate 20 mg
RxNorm normalized name: Ad5-nCoV
DrugBank: Ad5-nCoV (DB15655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg NCO-48 Fumarate over 28 days of therapy
Trial: NCT04629976
Drug: Tenofovir Alafenamide 25 mg
RxNorm normalized name: tenofovir alafenamide 25 MG
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg over 28 days of therapy
Trial: NCT04804904
Drug: TQ-B3101
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3101 oral capsule
Trial: NCT06013319
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
Trial: NCT05030597
Drug: 68Ga-DOTA-FAPI
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
Trial: NCT04705350
Drug: Zampilimab
RxNorm normalized name: Zampilimab
DrugBank: Zampilimab (DB16381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
Trial: NCT04173390
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
Trial: NCT05328076
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green is used to perform intraoperative angiography.
Trial: NCT01108913
Drug: Bimosiamose
RxNorm normalized name: Bimosiamose
DrugBank: Bimosiamose (DB06197)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04472949
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab: 1500 mg iv
Trial: NCT04472949
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin: AUC 5 mg/mL/min iv
Trial: NCT04472949
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide: 100 mg/m2 iv
Trial: NCT00002306
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05798819
Drug: GLS-010
RxNorm normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05798819
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT05798819
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05798819
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05798819
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion